Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMTPQUA)

Drug Name

LY-2624803 Drug Info

Synonyms

HY-10275; Insomnia therapy, Hypnion; Insomnia therapy, Lilly; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Hypnion; Dual-acting oral H1 receptor inverse agonist/5-HT 2a receptor modulator (insomnia), Lilly

Indication

Disease Entry	ICD 11	Status	REF
Insomnia	7A00-7A0Z	Phase 2	[1]

Cross-matching ID

PubChem CID: 11567064
CAS Number: CAS 879409-35-5
TTD Drug ID: DMTPQUA

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H1 receptor (H1R)	TTTIBOJ	HRH1_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Histamine H1 receptor (H1R)	DTT	HRH1	5.972	5.7	5.816	6.002

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Insomnia

ICD Disease Classification

7A00-7A0Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histamine H1 receptor (H1R)	DTT	HRH1	6.74E-01	0.13	0.43

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT00784875) An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia. U.S. National Institutes of Health.
2	Current Phase II investigational therapies for insomnia. Expert Opin Investig Drugs. 2015 Mar;24(3):401-11.